Topics

Latest "Pharvaris Gets 66mm Series" News Stories

05:58 EST 17th November 2019 | BioPortfolio

Here are the most relevant search results for "Pharvaris Gets 66mm Series" found in our extensive news archives from over 250 global news sources.

More Information about Pharvaris Gets 66mm Series on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharvaris Gets 66mm Series for you to read. Along with our medical data and news we also list Pharvaris Gets 66mm Series Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharvaris Gets 66mm Series Companies for you to search.

Showing "Pharvaris Gets 66mm Series" News Articles 1–25 of 2,800+

Saturday 16th November 2019

Xenotransplant Developer @eGenesisBio Raises $100M in Series B Financing: http://ow.ly/CoxB50x67KN pic.twitter.com/NrOfum95qA

Xenotransplant Developer @eGenesisBio Raises $100M in Series B Financing: http://ow.ly/CoxB50x67KN  pic.twitter.com/NrOfum95qA


Lab Connections Co-Sponsors Seminar Series on Analysis of Natural, Synthetic Polymers

Lab Connections (Marlborough, MA), a Mocon (Minneapolis) company, is co-sponsoring a seminar series on advanced techniques for the analysis of natural and synthetic polymers in the industrial, pharmaceutical, biotechnology, and food industries...

NeRRe Therapeutics pushes leads by €26m Series B financing


InflaRX raises US$55m in Series D round

Anaveon bags CHF35m series A financing

Friday 15th November 2019

International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019

CARLSBAD, CA / ACCESSWIRE / November 15, 2019 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced operating results for the three and nine months ended September 30, 2019. "A...

12 Cases of Vaping-Related Lung Injury Described in One Hospital

FRIDAY, Nov. 15, 2019 -- Twelve cases of electronic cigarette, or vaping, product use-associated lung injury (EVALI) from a single institution have been described in a case series published online Nov. 8 in The Lancet Respiratory Medicine. Aleksandr...

LUNAC announces spin out with £2.65 million funding to develop advanced anticoagulants

LUNAC Therapeutics today announced it has spun out of the University of Leeds with £2.65M funding in the first close of a Series A financing round.

EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform

The purpose of this funding round, which will be split into three tranches, is to progress the late-stage clinical development of EpicentRx’s lead anticancer agent, RRx-001, and proprietary The post EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform appeared first on Pharmaceutical Business review.

Thursday 14th November 2019

I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced that National Medical Products Administration (NMPA) approved its IND

Sera Prognostics closes $36mm Series D round

Sera Prognostics Inc. (proteomics tests for the early prediction of preterm birth defects and other pregnancy-related complic...

Series C lands $100mm for Avidity

Avidity Biosciences Inc. (developing Antibody-Oligonucleotide Conjugates for rare muscle disorders and other serious conditio...

Startup X-37 Raises $14.5M to Expand on AI-Powered Drug Discovery

Launched just last year, artificial intelligence-powered drug discovery company X-37 now has raised $14.5 million in Series A financing to expand its development programs. Co-founded by Atomwise and a team from Velocity Pharmaceutical Development, the San Francisco, CA-based company uses Atomwise’s AI platform for structure-based drug design to screen chemical compounds against pharmaceutical ta...

Horizon Fitness Brings the Streaming Workout Revolution to the Masses with New IC7.9 Indoor Cycle and 7.8AT Treadmill

Expanded home cardio lineup easily syncs with popular streaming fitness classes Horizon Fitness, a leading provider of high-performance home exercise equipment, continues to redefine the in-home cardio experience with the introduction of the Studio Series indoor cycle and treadmills. The new product lineup makes it virtually effortless for users to stream any live and on-demand fitness class of ...

FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List

Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been named to FORTUNE Magazine’s 2019 “Best Workplaces for Parents” list, which highlights companies that best support employees, regardless of parenting status, as well as offer quality benefits including generous parental leave, adoption, flexible scheduling and dependent health care options. Horizon ranked 19 out of 50 c...

X-37 Announces $14.5 Million Series A

X-37, LLC, an artificial intelligence-enabled drug discovery company, announced today that it has closed a $14.5 million Series A financing. The funding round was led by DCVC Bio and was joined by Alpha Intelligence Capital and Hemi Ventures. The Series A funding will be used to expand the number of drug development programs at X-37 and to advance identified drug leads through laboratory and prec...

Apple Launches Three Innovative Studies Today in the New Research App

The Apple Heart and Movement, Women’s Health and Hearing Studies Now Open for Enrollment Apple® today announced that customers in the US can enroll in three landmark health studies — the Apple Women’s Health Study, the Apple Heart and Movement Study, and the Apple Hearing Study. Conducted in partnership with leading academic and research institutions, these multi-year longitudinal studies...

Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference

Presentation on Thursday, November 21st at 12:25pm ET Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will present at the PCG Spotlight Series Conference taking place on Thursday, November 21st at the Harvard Club, 35 West 44th Str...

Financing round brings in $36M for Sera Prognostics

A round of Series D financing has pulled in $36 million for prenatal diagnostics company Sera Prognostics, which plans to use -More- 

LUNAC Therapeutics spun out to develop next generation anticoagulants, and announces Series A funding round.

  Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by Epidarex Capital and University of Leeds Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with mi...

LUNAC Therapeutics Spun out to Develop Next Generation Anticoagulants, and Announces Series A Funding Round

Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by Epidarex Capital and University of Leeds LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced it has spun...

Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results

Reminder: Company to Host Investor Call Today at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported third quarter 2019 results a...

Wednesday 13th November 2019

Community Health Systems Announces Early Tender Results to Previously Announced Exchange Offer

Community Health Systems, Inc. (the “Company”) (NYSE:CYH) today announced the results, as of 5:00 p.m., New York City time, on November 13, 2019 (the “Early Tender Deadline”), of an offer by its wholly owned subsidiary, CHS/Community Health Systems, Inc. (the “Issuer”), to exchange (the “Exchange Offer”) a combination of (i) $700 million aggregate principal amount of its new 8.000...

Biotech In-Demand Jobs: Computer and Information Research Scientists

In the last article on our series of common biopharma careers, we take a close look at what it takes to become a successful computer and information research scientist.

Advances in the detection of the postoperative progress of abdominal aortic aneurysm

(Universitat Pompeu Fabra - Barcelona) A study published in Frontiers in Bioengineering and Biotechnology by a team of researchers from BCN MedTech with the VICOMTech Foundation in San Sebastian, the BioDonostia Health Research Institute and Donostia University Hospital, offers a promising methodology for post-operative CTA time-series registration and subsequent aneurysm biomechanical strain anal...


Quick Search

News Quicklinks